Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational studyKeiko Ihara, Tsubasa Takizawa, Seiya Ohtani et al.|The Journal of Headache and Pain|2023Cited by 82
Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysisTsubasa Takizawa, Jin Nakahara, Seiya Ohtani et al.|BMC Neurology|2022Cited by 67
Incidence of headache after COVID-19 vaccination in patients with history of headache: A cross-sectional studyKoji Sekiguchi, Tsubasa Takizawa, Narumi Watanabe et al.|Cephalalgia|2021Cited by 65
Switching between anti-calcitonin gene-related peptide monoclonal antibodies: A comparison of monthly and quarterly dosingKeiko Ihara, Tsubasa Takizawa, Seiya Ohtani et al.|Journal of the Neurological Sciences|2023Cited by 23
CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache societyTsubasa Takizawa, Jin Nakahara, Keiko Ihara et al.|The Journal of Headache and Pain|2024Cited by 17